Two healthcare data companies joined forces on Thursday to address historical diversity and inclusion challenges in clinical trials. Atropos Health, a Palo Alto-based company that delivers clinical data to physicians at the point of…
Continue Reading
During the global pandemic, the world saw firsthand how essential clinical trials were in developing medicines to improve health and extend human life. Clinical research sites, including academic medical centers (AMC), non-AMCs and professional…
Continue Reading
What You Should Know:
Data Driven Insights Enabled by Merck and Amgen Fundings
As the most extensive repository of its kind, this data lake empowers biopharmaceutical companies by providing crucial insights necessary for advancing diagnostic and…
Continue Reading
What You Should Know:
– NVIDIA announced the launch of a cloud service for medical imaging AI, designed to streamline and accelerate the development of specialized AI models.
– The NVIDIA MONAI cloud APIs, built on…
Continue Reading
These numbers are astounding.
Between 1999 and 2021, nearly 645,000 people died of an opioid overdose. That’s in 22 years. Since the end of the Revolutionary War in 1783, the cumulative deaths from all American…
INVEST 2024 will be back at the Ritz Hotel in Chicago, May 21-22, and we are once again on the hunt for novel startups who will pitch LIVE in front of venture capitalist judges….
Continue Reading
From time to time, the FDA convenes an outside group of experts to weigh in on an experimental drug or medical device, or to offer insight on a scientific matter that raises questions. The…
Continue Reading
From left to right: Marissa Plescia, reporter at MedCity News; and Merith Basey, executive director of Patients For Affordable Drugs
After much anticipation and a bevy of (ongoing) lawsuits, the U.S. government is finally beginning…
What You Should Know:
Mission Bio, a leader in single-cell multi-omic solutions for precision medicine, announced the commercial launch of the Tapestri® Single-cell MRD (scMRD) AML Multiomics Assay.The company designed the scMRD AML Multiomics Assay to bring…
Continue Reading
Perspectives on the digital therapeutics industry tend to reveal the bias of the prognosticator as a glass-half-full optimist or glass-half-empty pessimist. Not enough clinical data vs. inadequate payer reimbursement. Many of the apps produced…
Continue Reading
